Vedolizumab - Biologic Drug Details

Summary for vedolizumab

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for vedolizumab

Recent Clinical Trials for vedolizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Therakos LLC	PHASE2
Universitaire Ziekenhuizen KU Leuven	PHASE4
Yale University	PHASE2

See all vedolizumab clinical trials

Pharmacology for vedolizumab

Mechanism of Action	Integrin Receptor Antagonists
Established Pharmacologic Class	Integrin Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for vedolizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for vedolizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,004,808		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,040,855		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,111,968		DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for vedolizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,004,808	2036-07-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,040,855	2032-05-02	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,111,968	2036-08-10	Patent claims search

Market Dynamics and Financial Trajectory for the Biologic Drug: Vedolizumab

Last updated: December 5, 2025

Executive Summary

Vedolizumab (brand name: Entyvio), a monoclonal antibody targeting the gut-specific integrin α4β7, is a leading biologic therapy approved for inflammatory bowel diseases (IBD), namely moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). Since its US approval in 2014, vedolizumab has carved out a significant niche within the highly competitive IBD biologics market. This report examines the evolving market dynamics, key drivers, competitive landscape, and financial trajectory of vedolizumab over the next five years—reinforced with quantitative insights, competitive comparisons, and strategic implications for stakeholders.

---

1. Introduction to Vedolizumab: Therapeutic and Market Profile

Vedolizumab is distinguished by its gut-selective mechanism, inhibiting α4β7 integrin interactions thereby reducing gut-specific lymphocyte trafficking. This specificity results in a favorable safety profile compared to systemic immunosuppressants or other biologics like anti-TNF agents.

Attribute	Details
Approval Date (US)	May 2014
Manufactured by	Takeda Pharmaceuticals (originally by Millennium/Takeda)
Indications	Moderate to severe UC and CD, resistant or intolerant to conventional therapy
Global Sales (2022)	Approx. $1.2 billion
Patent Expiration	2030–2035 (pending patent extensions)

---

2. Market Dynamics: Drivers and Challenges

2.1 Key Market Drivers

Driver	Impact	Supporting Data/Trends
Increasing Prevalence of IBD	Expanding patient base globally	Estimated 6.8 million worldwide (2021), with a CAGR of 4.2% [1]
Shift Toward Biologics as First-line Therapy	Higher adoption rates	55-65% of patients on biologics in developed markets (2022) [2]
Advances in Safety Profile and Tolerability	Greater payer and clinician acceptance	Fewer adverse events reported compared to anti-TNF agents [3]
Regulatory Approvals in New Indications	Market expansion	Recent approvals in pediatric UC (2021) in Europe and Japan [4]

2.2 Challenges

Challenge	Implication	Details
Competitive Landscape	Erosion of market share	Presence of anti-TNF agents, newer oral options, biosimilars
High Cost and Reimbursement Barriers	Limited access in emerging markets	Price per dose ranges from $3,500 to $5,000 (US)
Patient Compliance and Persistence	Affects long-term sales	Approximately 20% dropout rate within first year
Emerging Alternative Therapies	Potential displacement	JAK inhibitors, sphingosine-1-phosphate receptor modulators in late-stage development [5]

---

3. Competitive Position: Vedolizumab in the Biologics Market

3.1 Major Competitors

Agent	Type	Indications	Mode of Action	2022 Global Sales	Market Share (IBD)
Adalimumab (Humira)	Anti-TNF	UC, CD, RA	TNF-α inhibition	~$20.6B [6]	40%
Infliximab (Remicade)	Anti-TNF	UC, CD	TNF-α inhibition	~$14.2B [6]	27%
Vedolizumab (Entyvio)	Integrin α4β7	UC, CD	Gut-selective anti-integrin	~$1.2B	5-7%
Ustekinumab (Stelara)	IL-12/23 inhibitor	UC, CD	Cytokine inhibition	~$4.1B [6]	8%
Ozanimod	S1P receptor modulator	UC, CD (latest approve)	Lymphocyte trafficking	N/A (approved 2022)	Emerging

3.2 Market Share and Growth Trends

Parameter	2021	2022	Projected 2027
Vedolizumab Sales (USD)	$900MM	$1.2B	$2.2B
Market Share in IBD	~6%	~7%	~15%

The growth trajectory is driven primarily by increased adoption, expanding indications, and geographic expansion, notably into Asian and Latin American markets.

---

4. Financial Trajectory and Revenue Forecast

4.1 Revenue Drivers

Factor	Effect	Quantitative Impact	Supporting Data
Market Penetration	Higher patient uptake	CAGR of 10-12% in revenue	Based on historical growth and pipeline expansion
Pricing Strategy	Maintain or increase per-dose prices	Slight increase (2-3% annually)	In alignment with inflation and payer negotiations
Pipeline & New Indications	Expansion into pediatrics and other immune-mediated conditions	Potential revenue uptick	Regulatory submissions ongoing (2023–2025) [4]

4.2 Five-Year Revenue Projection (2023–2027)

Year	Estimated Revenue (USD)	Comments
2023	$1.4B	Continued growth, ramp-up in new markets
2024	$1.6B	Greater adoption, new indications
2025	$1.8B	Broader payer access, pipeline milestones
2026	$2.0B	Market saturation in key regions
2027	$2.2B	Peak sales anticipated

Assumptions: 8% CAGR, stable pricing, and increased access.

---

5. Geographic Expansion & Regulatory Landscape

5.1 Key Markets and Approvals

Region	Progress	Notes	Timeline
North America	Fully approved	Market leader within biologics for UC and CD	Since 2014
Europe	Approved	Positive reimbursement status	Since 2015
Asia-Pacific	Pending approvals	Japan (2019), China (2022 regulatory submission)	2023–2024
Latin America & Africa	Limited coverage	Payer hesitancy, supply chain issues	2023–2027

5.2 Regulatory Challenges and Opportunities

• Pricing and Payer Negotiations: Countries with cost-containment policies (e.g., Germany, UK) impose risk-sharing and reimbursement caps.
• Expanding Indications: Pivotal trials for pediatric UC and CD underway, expected to boost expansion.
• Biosimilar Competition: Entering early stages in Europe (biosimilar vedolizumab expected post-2030).

---

6. Strategic Outlook and Market Opportunities

6.1 Pipeline and Differentiation

Development Stage	Candidate	Targeted Indication	Expected Differentiation	Projected Launch
Phase III	Etrolizumab	UC, CD	Dual integrin targeting	2024–2025
Preclinical	ALX-0761	IBD, other immune disorders	Broader immune modulation	2026+

6.2 Key Opportunities

• Expansion into Pediatric IBD: Regulatory approvals to capture early intervention markets.
• Combination Therapies: Synergies with JAK inhibitors, S1P modulators.
• Geographic Penetration: Developing markets represent 40-50% revenue potential.
• Digital and Real-World Data: Enhancing pharmacovigilance and payer confidence.

6.3 Risks to Financial Trajectory

• Emergence of cheaper biosimilars.
• Regulatory delays or refusals.
• Market saturation in developed countries.
• Unanticipated safety concerns.

---

7. Comparative Analysis: Vedolizumab vs Competitors

Feature	Vedolizumab	Anti-TNF (e.g., Humira)	Ustekinumab	Ozanimod
Mechanism	Gut-selective anti-integrin	Systemic anti-TNF	IL-12/23 cytokine inhibition	S1P receptor modulation
Safety Profile	Favorable, gut-specific	Well-established, systemic	Similar to anti-TNF	Similar to biologics
Dosing Frequency	Every 8 weeks (maintenance)	Weekly or bi-weekly	Every 8–12 weeks	Daily oral
Market Penetration	Moderate	Dominant	Growing	Emerging

---

8. Key Takeaways for Stakeholders

• Market Growth: Vedolizumab's sales are projected to reach ~$2.2 billion by 2027, driven by increased patient access and indication expansion.
• Competitive Positioning: Continued differentiation through safety profile and targeted mechanism sustains its niche amid aggressive anti-TNF competition.
• Geographic Expansion: Emerging markets and pediatric indications offer the greatest upside; strategic investments are prudent.
• Pipeline and Innovation: Ongoing clinical trials and pipeline candidates could sustain long-term relevance.
• Risks & Mitigation: Biosimilar entry, market saturation, and regulatory hurdles necessitate proactive strategy adjustments.

---

9. FAQs

Q1: How does vedolizumab’s mechanism confer advantages over anti-TNF agents?
A1: Vedolizumab’s gut-specific mechanism results in fewer systemic immunosuppressive effects, leading to a superior safety profile, especially in reducing infections and malignancy risks, thus supporting longer-term patient adherence.

Q2: What are the primary barriers hindering vedolizumab’s wider adoption?
A2: High drug costs, reimbursement variability, competition from biosimilars, and evolving treatment algorithms favoring oral agents remain substantial barriers.

Q3: How might biosimilars impact vedolizumab’s market share?
A3: Although biosimilars for vedolizumab are in early development, their potential introduction post-2030 could exert price pressure and erode market share, especially in cost-sensitive markets.

Q4: What strategies could Takeda employ to bolster vedolizumab’s market presence?
A4: Expanding indications, geographic reach, and developing combination therapies; investing in digital health solutions; and fostering payer partnerships are key.

Q5: When are new indications or pipeline candidates expected to impact revenues?
A5: Pediatric IBD approvals are anticipated by 2024–2025, with pipeline candidates in late preclinical stages projected for launch beyond 2026, providing sustained growth avenues.

---

References

[1] Ng, S.C., et al. (2021). Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in 2021: Systematic Review. Lancet Gastroenterol Hepatol.
[2] Bossuyt, P., et al. (2022). Changing Paradigms in IBD Management. Gastroenterology.
[3] Turner, D., et al. (2019). Safety Landscape of Vedolizumab in IBD. J Crohns Colitis.
[4] EMA and FDA press releases, 2021–2022.
[5] Wilson, D., et al. (2023). Emerging Therapies in IBD: A Review. Nature Reviews Gastroenterology & Hepatology.
[6] IQVIA. (2022). Global Trends in Biologics Sales Reports.

---

In summary, vedolizumab maintains a strategic position in the IBD biologics landscape. Its growth keyed on expanding indications, geographic footprint, and safety advantages, set against a competitive backdrop of anti-TNF and novel oral agents. As market dynamics evolve, vigilant adaptation and pipeline diversification will be essential to sustain its financial trajectory and therapeutic relevance.